TAS-102 plus bevacizumab for first-line advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, TAS-102 (an oral chemotherapy) and bevacizumab (a targeted therapy), as a first treatment for advanced colorectal cancer that has spread. It may be an option for people who cannot have or do not tolerate standard combination chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has spread and you have not had chemotherapy or targeted therapy for it before.
- You are at least 18 years old and your doctor expects you to live at least 3 more months.
- Your cancer is measurable on scans (at least one tumor that can be measured).
- Your blood counts, liver, and kidney function are within certain limits (your doctor will check).
- You are willing to use effective birth control during and for 6 months after treatment (if applicable).
- You do not have other serious illnesses like active infection, uncontrolled diabetes, heart problems, or bleeding issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, TAS-102 and bevacizumab, as a follow-up maintenance treatment for people with advanced colorectal cancer. The goal is to see if this treatment can keep the cancer from growing after initial chemotherapy and bevacizumab therapy.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests a new combination—fruquintinib (a targeted pill) plus TAS-102 (another chemo pill)—against a standard regimen of bevacizumab (Avastin) plus TAS-102 for people whose advanced colorectal cancer has continued to grow after multiple prior treatments.
This trial tests a new drug, TQB2930, combined with chemotherapy (with or without bevacizumab) for advanced colorectal cancer that cannot be removed by surgery. It's designed for people whose tumors are HER2-positive and have not responded to standard treatments.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.